These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24649927)

  • 1. Targeting TDP-43 in neurodegenerative diseases.
    Budini M; Baralle FE; Buratti E
    Expert Opin Ther Targets; 2014 Jun; 18(6):617-32. PubMed ID: 24649927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TDP-43 post-translational modifications in health and disease.
    Buratti E
    Expert Opin Ther Targets; 2018 Mar; 22(3):279-293. PubMed ID: 29431050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of TDP-43 in the pathogenesis of ALS and FTLD.
    Baralle M; Buratti E; Baralle FE
    Biochem Soc Trans; 2013 Dec; 41(6):1536-40. PubMed ID: 24256250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAR DNA-binding protein of 43 kDa (TDP-43) and amyotrophic lateral sclerosis (ALS): a promising therapeutic target.
    Ojaimi YA; Dangoumau A; Alarcan H; Hergesheimer R; Vourc'h P; Corcia P; Lanznaster D; Blasco H
    Expert Opin Ther Targets; 2022 Jun; 26(6):575-592. PubMed ID: 35652285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting RNA binding proteins involved in neurodegeneration.
    Romano M; Buratti E
    J Biomol Screen; 2013 Oct; 18(9):967-83. PubMed ID: 23954928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?
    Baloh RH
    Curr Opin Neurol; 2012 Dec; 25(6):701-7. PubMed ID: 23041957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unconventional features of C9ORF72 expanded repeat in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
    Vatovec S; Kovanda A; Rogelj B
    Neurobiol Aging; 2014 Oct; 35(10):2421.e1-2421.e12. PubMed ID: 24836899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structural integrity of TDP-43 N-terminus is required for efficient aggregate entrapment and consequent loss of protein function.
    Romano V; Quadri Z; Baralle FE; Buratti E
    Prion; 2015; 9(1):1-9. PubMed ID: 25635624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neurodegenerative disorders and TDP-43].
    Nonaka T; Inukai Y; Arai T; Hasegawa M
    Brain Nerve; 2009 Feb; 61(2):161-6. PubMed ID: 19235466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TDP-43: an emerging new player in neurodegenerative diseases.
    Wang IF; Wu LS; Shen CK
    Trends Mol Med; 2008 Nov; 14(11):479-85. PubMed ID: 18929508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [RNA processing TDP-43 protein has a main pathological role in FTLD and ALS].
    Koza P
    Postepy Biochem; 2015; 61(2):159-67. PubMed ID: 26689008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies.
    Jo M; Lee S; Jeon YM; Kim S; Kwon Y; Kim HJ
    Exp Mol Med; 2020 Oct; 52(10):1652-1662. PubMed ID: 33051572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia.
    Mackenzie IR; Rademakers R; Neumann M
    Lancet Neurol; 2010 Oct; 9(10):995-1007. PubMed ID: 20864052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Significance of TDP-43 Mutations in Disease.
    Buratti E
    Adv Genet; 2015; 91():1-53. PubMed ID: 26410029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TDP-43 pathology in polyglutamine diseases: with reference to amyotrphic lateral sclerosis.
    Toyoshima Y; Takahashi H
    Neuropathology; 2014 Feb; 34(1):77-82. PubMed ID: 23889603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular link between inefficient GluA2 Q/R site-RNA editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients.
    Yamashita T; Kwak S
    Brain Res; 2014 Oct; 1584():28-38. PubMed ID: 24355598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis.
    Kwong LK; Uryu K; Trojanowski JQ; Lee VM
    Neurosignals; 2008; 16(1):41-51. PubMed ID: 18097159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
    Riku Y; Watanabe H; Yoshida M; Tatsumi S; Mimuro M; Iwasaki Y; Katsuno M; Iguchi Y; Masuda M; Senda J; Ishigaki S; Udagawa T; Sobue G
    JAMA Neurol; 2014 Feb; 71(2):172-9. PubMed ID: 24378564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAR DNA binding protein-43 and fused in sarcoma/translocated in liposarcoma protein in two neurodegenerative diseases.
    Wang XN; Cui LY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Jun; 34(3):286-92. PubMed ID: 22776664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggregation of the 35-kDa fragment of TDP-43 causes formation of cytoplasmic inclusions and alteration of RNA processing.
    Che MX; Jiang YJ; Xie YY; Jiang LL; Hu HY
    FASEB J; 2011 Jul; 25(7):2344-53. PubMed ID: 21450909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.